Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer

Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer

Approximately seventy percent of ovarian cancer patients succumb to the disease within the first 5 years of diagnosis, even after successful surgery and effective chemotherapy treatment. A small subset of chemotherapy resistant cancer stem cells (CSCs) cause relapse of ovarian cancers. This study in...

Full description

Bibliographic Details
Main Authors: Elif Kadife, Emily Chan, Rodney Luwor, George Kannourakis, Jock Findlay, Nuzhat Ahmed
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Cancers
Subjects:
ovarian carcinoma
ascites
chemoresistance
chemotherapy
Dasatinib
paclitaxel
cancer stem cells
Online Access:https://www.mdpi.com/2072-6694/11/2/243

Similar Items

Similar Items